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ThisstudywasconductedtodeterminethepotentialofbisphenolA
(BPA) to induce functional and/or morphological effects to the
nervous system of F1 offspring from dietary exposure during
gestation and lactation according to the Organization for Economic
Cooperation and Development and U.S. Environmental Protection
Agencyguidelinesforthestudyofdevelopmentalneurotoxicity.BPA
wasofferedtofemaleSprague-DawleyCrl:CD(SD)rats(24perdose
group) and their litters at dietary concentrations of 0 (control), 0.15,
1.5, 75, 750, and 2250 ppm daily from gestation day 0 through
lactation day 21. F1 offspring were evaluated using the following
tests: detailed clinical observations (postnatal days [PNDs] 4, 11, 21,
35, 45, and 60), auditory startle (PNDs 20 and 60), motor activity
(PNDs13,17,21,and61),learningandmemoryusingtheBielwater
maze (PNDs 22 and 62), and brain and nervous system neuropa-
thology andbrainmorphometry(PNDs21and 72).ForF1 offspring,
there were no treatment-related neurobehavioral effects, nor was
there evidence of neuropathology or effects on brain morphometry.
Based on maternal and offspring body weight reductions, the
no-observed-adverse-effect level (NOAEL) for systemic toxicity was
75 ppm (5.85 and 13.1 mg/kg/day during gestation and lactation,
respectively), with no treatment-related effects at lower doses or
nonmonotonicdoseresponsesobservedforanyparameter.Therewas
no evidence that BPA is a developmental neurotoxicant in rats, and
the NOAEL for developmental neurotoxicity was 2250 ppm, the
highest dose tested (164 and 410 mg/kg/day during gestation and
lactation, respectively).
Key Words: bisphenol A; CAS No. 80-05-7; developmental
neurotoxicity; OECD 426; neurobehavior; learning and memory;
neuropathology; morphometry.
Bisphenol A (BPA) is a high–production volume chemical
used primarily to manufacture polycarbonate plastics and
epoxy resins, and is considered to have weak estrogen-like
properties. Human exposure to low doses (typically <0.1 lg/kg
body weight/day; Dekant and Vo ¨lkel, 2008) of BPA occurs
principally through food contact use of these materials (e.g.,
polycarbonate plastic is used in plastic bottles and epoxy resins
are used to coat food and beverage containers; EFSA, 2006;
FDA, 2008). Some expert panel and government reviews
(Chapin et al., 2008; FDA, 2008; Health Canada, 2008) of the
extensive BPA literature indicated the need for the develop-
ment of additional data to examine the potential of dietary BPA
to produce functional or morphological effects on the
developing nervous system. In a previous multigeneration
reproduction study that incorporated behavioral measures
following low-dose exposure, BPA had no effects on F1 or
F2 developmental landmarks, open-ﬁeld behavior, cognitive
tasks (i.e., T-maze and Biel maze), or brain weights at doses
ranging from 0.2 to 200 lg/kg/day (Ema et al., 2001).
However, a developmental neurotoxicity study (DNT) con-
ducted according to regulatory guidelines has not been
published.
Therefore, the present study was conducted with BPA oral
exposure in rats in compliance with the most current
developmental neurotoxicity guidelines, Organization for
Economic Cooperation and Development (OECD) Test
Guideline (TG) 426 (OECD, 2007a) and U.S. Environmental
Protection Agency (EPA) OPPTS Guideline 870.6300 (U.S.
EPA, 1998), and in compliance with Good Laboratory Practice
(GLP) principles (OECD, 1998, 2002; U.S. EPA, 1989) to
examine widely accepted and validated neurobehavioral and
neuropathological end points. The study design exceeded the
EPA and OECD guidelines by evaluation, and external peer
review, of neuropathology and brain morphometry for all
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the use of ﬁve (vs. three) dietary levels of BPA, ranging from
very low concentrations to concentrations sufﬁcient to achieve
maternal toxicity. As speciﬁed in the cited guidelines, positive
control data, using reference chemicals in Sprague-Dawley rats,
established the reliability and sensitivity of the neurotoxicology
test methods under the conditions used for the study. The study
used the rat, the preferred test species for DNT studies according
to the guidelines; the Sprague-Dawley strain was used as there
was a large database with historical control (untreated) and
positive control data for DNT end points.
Dietary concentrations of BPA in this study (0, 0.15, 1.5, 75,
750, and 2250 ppm; mean target doses ~0, 0.01, 0.1, 5, 50, and
150 mg/kg/day) were selected to provide doses that spanned
the range from low doses used in some published studies
reporting developmental neurotoxicity (Chapin et al., 2008)t o
a high dose that was anticipated to result in systemic toxicity in
the pregnant rat. This range provided for evaluation of potential
low-dose effects as well as potential nonmonotonic dose-
response relationships. The high dose was selected to produce
maternal and neonatal body weight effects without resulting in
developmental delays that would signiﬁcantly impact the
neurobehavioral measurements (speciﬁed by the guideline).
The F1 animals in the present study were exposed to the test
substance in utero (Domoradzki et al., 2003), as well as via the
milk while nursing (Snyder et al., 2000) and via direct
consumption of the diet during the third week of the lactation
period. To maximize exposure, the diets were maintained at
a constant concentration (i.e., diet was not adjusted to provide
a consistent milligram per kilogram per day dose of BPA)
during lactation, although increased feed consumption by the
dam (to support milk production) results in a higher dose
during this period.
The objectives of this study were to determine the potential
of BPA, administered in the feed to Sprague-Dawley rats, to
induce functional and/or morphological effects in the nervous
system that may arise in the offspring from exposure of the
mother during pregnancy and lactation. The results of this
guideline-based study are expected to be useful for human
health risk assessment as these end points are generally
recognized as relevant to neurodevelopment in humans.
MATERIALS AND METHODS
The present study was conducted in compliance with OECD (TG 426) and
U.S. EPA OPPTS (870.6300) guidelines and followed U.S. EPA and OECD
principles of GLPs. The study design exceeded the guideline requirements as
there were more dose groups, to accommodate the typical dose range (i.e., to
induce some maternal toxicity and establish a no-observed-adverse-effect level
[NOAEL]), as well as use of a low-dose range. In addition, neuropathology and
morphometry were conducted for animals in all groups to ensure the evaluation
of potential low-dose effects; the guidelines specify examination of only control
and high-dose tissues unless there is evidence of a treatment-related lesion in
high-dose animals.
Test Substance and Dose Formulations
BPA (4,4#-isopropylidene-2-diphenol; CAS No. 80-05-7) was received as
a white granular solid (purity >99.5%) from Acros Organics NV (Fairlawn,
NJ). The feed used for preparation of the test diets was Certiﬁed Ground
Rodent LabDiet 5002 (PMI Nutrition International, LLC, St Louis, MO). Diets
(0, 0.15, 1.5, 75, 750, and 2250 ppm BPA in feed) were formulated using stock
solutions of BPA dissolved in acetone. For the 0.15- and 1.5-ppm dose groups,
the BPA solution was added to the feed and blended. For the 75-, 750-, and
2250-ppm dose groups, a concentrated premix was prepared using the BPA
acetone stock solutions, and the test diets were prepared by dilution of this
premix. For the control diet, a volume of acetone equal to the largest amount
added for the test diets was added. The homogeneity and stability of BPA in the
diets at concentrations of 0.010 and 7500 ppm were established. The test diets
were prepared at least biweekly and stored at room temperature or in a freezer
in accordance with stability data.
BPA diet concentrations were conﬁrmed by analysis of all batches of feed
that were presented to the animals with a limit of detection and a limit of
quantitation (LOQ) of 0.0032 and 0.010 ppm, respectively. Only formulations
that satisﬁed the acceptability standard (mean concentration within ±15% of the
target concentration) were considered acceptable for use. The analytical range
for all diets used was 86.6–113% of the target concentration for BPA. All
analyses of control diet used in the study were below the LOQ.
Animals and Husbandry
One hundred eighty (180) virgin female Sprague-Dawley Crl:CD (SD) rats
(Charles River Laboratories, Inc., Raleigh, NC) were received in two
shipments, 90 per shipment, 4 weeks apart. The animals were approximately
70 days old upon receipt. Animals from the ﬁrst and second shipments were
designated as cohorts 1 and 2, respectively. Use of cohorts was necessary to
accommodate the logistics of data collection due to the number and size of the
dose groups. Each cohort consisted of 12 mated females per dose group.
Sexually mature resident males of the same strain and source, maintained
exclusively for mating, were used to induce pregnancy. Each male was used to
sire only one litter. Each female judged to be in good health and meeting the
acceptable body weight requirement (minimum of 220 g) was paired with
a male for mating at approximately 12 weeks of age.
Each F0 female was uniquely identiﬁed by a Monel (National Band and Tag
Co., Newport, KY) metal ear tag. The F1 offspring selected to continue on
study were identiﬁed by foot markings at the end of parturition and uniquely
identiﬁed by a Monel metal ear tag following weaning.
All F0 females and their offspring were housed in the same room from
arrival to termination; the animals from the two cohorts were housed in separate
similar environmentally controlled rooms. The F0 females were housed
individually in clean suspended wire mesh stainless steel cages from arrival
until gestation day (GD) 18. On GD 18, females were transferred to
polyphenylsulfone RaTEMP thermoplastic rat cages (Allentown, Inc., Allen-
town, NJ) with ground corncob nesting material (Bed O’Cobs; The Andersons,
Cob Products Division, Maumee, OH) and remained in these cages either
individually or with their litters until euthanasia. Ground corncob nesting
material is the standard bedding used at WIL Research Laboratories, LLC;
therefore, for consistency with historical control data, the same bedding was
used in the present study. The F1 offspring remained with their littermates in the
polyphenylsulfone cages through postnatal day (PND) 27. From PND 28 until
euthanasia, the F1 offspring were housed individually in suspended wire mesh
stainless steel cages. Animals were housed in accordance with the Guide for
the Care and Use of Laboratory Animals (National Research Council, 1996).
The animal facilities at WIL Research Laboratories, LLC, are accredited by the
Association for Assessment and Accreditation of Laboratory Animal Care
International. The animal room temperature was set to 71 ± 5 F (22 ± 3 C), the
average daily relative humidity was set to 50 ± 20%, and a 12-h light cycle per
day was used.
Certiﬁed Ground Rodent LabDiet 5002 was available ad libitum during the
study. The phytoestrogen content (as total aglycone units: sum of the
concentrations of genistin, genistein, daidzin, daidzein, glycitin, glycitein,
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312 ppm (NP Analytical Laboratories, St Louis, MO). Reverse osmosis–
puriﬁed (on-site) drinking water (City of Ashland, Water Supply and
Treatment, Ashland, OH) was available ad libitum from an automatic watering
system with metal lixits in each cage.
Study Design
The study consisted of 24 female rats per dose group; 12 mated females per
dose group in each of two cohorts spaced 4 weeks apart. Bred animals were
assigned to the control or one of ﬁve test substance–treated groups (Table 1)
using a computer program that assigned animals based on stratiﬁcation of the
GD 0 body weights. BPA was administered at a constant concentration (ppm)
in the diet from GD 0 through lactation day (LD) 21. Table 1 summarizes the
design for the F0 animals.
Experimental Evaluations
Maternal observations. All F0 females were allowed to deliver. The day of
parturition was designated as LD 0 (dams) and PND 0 (offspring). Pups were
sexed and examined for gross malformations, and the number of stillbirths and
live pups was recorded. The dam and litter remained together until weaning on
PND 21.
Observations for mortality and moribundity were made twice daily (A.M. and
P.M.) from GD 0 through LD 21. Clinical observations were recorded daily.
Twice-daily observations for dystocia (prolonged labor, delayed labor, or other
difﬁculties) were also made during the period of expected parturition. Females
were weighed on GDs 0, 3, 7, 10, 14, 17, and 20. Dams producing litters were
weighed on LDs 1, 4, 7, 11, 14, 17, and 21.
Feed consumption measurements were recorded along with the body weight
data. Mean test substance consumption (milligram per kilogram body weight
per day) for each group was determined by multiplying the concentration of
BPA in the diet (milligram BPA per gram of feed) by the gram per kilogram
body weight per day feed consumption value for each animal for each interval.
Offspring (F1) observations. Each litter was examined daily for survival.
To reduce variability due to differences in litter size, litters were reduced to
eight randomly selected pups of equal sex distribution, to the extent possible
within each litter on PND 4. As provided in the test guidelines, litters with six
pups or fewer, or that did not meet the sex ratio criteria (i.e., at least three pups
per sex) were not used for neurobehavioral or neuropathological evaluation
and were necropsied on PND 4. One male and one female pup from each litter
that was retained were randomly assigned to one of the evaluation subsets
(Table 2).
Observations for offspring mortality and moribundity were made daily from
the day of parturition through euthanasia. On PNDs 4, 11, and 21 and at weekly
intervals thereafter until euthanasia, each pup was removed from the home cage
and received a detailed physical examination. Individual pup body weights
were recorded on PNDs 1, 4, 7, 11, 14, 17, and 21 and at weekly intervals
thereafter until euthanasia.
Developmental landmarks. All pups were examined daily for surface
righting reﬂex beginning on PND 2 until attainment. Pups culled before
attaining righting reﬂex were eliminated from statistical analysis. For this test,
pups were placed in a supine position and allowed a maximum of 2 s for
righting (all four paws on the surface). Failure to return to an upright position in
the allotted time was considered a negative response. Female pups (one per
litter) were observed daily for vaginal patency (VP) beginning on PND 25
(Adams et al., 1985) and continuing until VP was present, with body weight
recorded on the day of attainment. Male pups (one per litter) were observed for
balanopreputial separation (PPS) beginning on PND 35 (Korenbrot et al., 1977)
and continuing until PPS was present, with body weight recorded on the day of
attainment.
Detailed clinical observations (F0 and F1 offspring). The detailed clinical
observations (DCO) were based on previously developed protocols (Gad, 1982;
Haggerty, 1989; Irwin, 1968; Moser et al., 1988, 1991; O’Donoghue, 1989).
The DCO contained observational components of a functional observational
battery and involved observing the individual animal outside of the home cage
in an open ﬁeld for 2 min (Table 3). DCO were conducted on all F0 females on
GDs 10 and 15, on all dams on LDs 10 and 21, and on F1 offspring on PNDs 4,
11, 21, 35, 45, and 60. Testing was performed by trained observers (without
knowledge of group assignment). A separate follow-up study to evaluate F1
pups using DCO on PNDs 4 and 11 was conducted following the present study
(see Supplementary data).
Motor activity (F1 offspring). Motor activity was measured for one male
and one female per litter on PNDs 13, 17, 21, and 61 using the Kinder Scientiﬁc
TABLE 1
Organization, Nominal Concentrations, and Target Doses
Group no. Diet
No. of females Dietary
concentration
(ppm)
Target dose
(mg/kg/day) Cohort 1 Cohort 2
1 Control
(basal diet)
12 12 0 0
2 BPA 12 12 0.15 0.01
3 BPA 12 12 1.5 0.1
4 BPA 12 12 75 5
5 BPA 12 12 750 50
6 BPA 12 12 2250 150
TABLE 2
Offspring Allocation and Testing Schedule for Behavioral
Assessments, Brain Weights, and Neuropathological/
Morphometric Evaluation
No. selected
(subset)
a Age Evaluation
1 pup/sex/
litter (A)
b
PNDs 4, 11,
21, 35, 45, 60
DCO
PNDs 13, 17,
21, 61
Motor activity
PNDs 20, 60 Auditory startle
PND 62 Learning and memory
(Biel water maze)
PND 72 Brain weights,
neuropathological
assessment, morphometry
(perfused)
1 pup/sex/
litter (B)
c
PND 22 Learning and memory
(Biel water maze)
1 pup/sex/
litter (C)
PND 21 Brain weights,
neuropathological
assessment, morphometry
(perfused)
1 pup/sex/
litter (D)
PND 21 Necropsy of all F1 animals
not selected for behavioral
evaluations
aOf the eight pups in each litter, one male and one female pup in each litter
was randomly assigned to each of the four subsets (A, B, C, or D).
bSubset A pups were examined for developmental landmarks. The same pups
were evaluated for DCO, motor activity, auditory startle, and learning and
memory (subset A).
cA different subset of pups was evaluated on PND 22 (subset B) than for
PND 62 (subset A).
DEVELOPMENTAL NEUROTOXICITY BPA RAT STUDY 169Motor Monitor System (Kinder Scientiﬁc, Poway, CA). Testing was performed
in a sound-attenuated room equipped with a white noise generation system set
to operate at 70 ± 10 decibels (dB(A)). Each chamber consisted of a series of
infrared photobeams surrounding a rectangular cage. Four-sided black
enclosures surrounded the cage and decreased the potential for distraction by
extraneous environmental stimuli. The calibration of each chamber was veriﬁed
before each test session. The testing of treatment groups was done according to
replicate sequence; no more than 24 animals were tested during a single
session. Each test session was 60 min in duration; total activities (interruption
of any photobeam) were recorded. These data were compiled into six 10-min
subintervals for tabulation and evaluation of intrasession habituation.
Auditory startle. An auditory startle response was measured for one male
and one female per litter on PNDs 20 and 60 using the Startle-Monitor System
(Kinder Scientiﬁc). Testing was performed in a sound-attenuated room
equipped with a white noise generation system set to operate at 70 ± 10
dB(A). Testing was performed following the DCO on PND 60. Animals were
placed individually in a rectangular enclosure of appropriate size, which was
enclosed in an individual isolation cabinet. Each compact cabinet measured
10.9 3 14 3 19.5 inches and was equipped with an internal light, a fan, two
viewing lenses, and a complete white noise generation system. Each enclosure
was equipped with a motion sensor. Each test session consisted of a 5-min
acclimation period with broadband background ‘‘white’’ noise (65 ± 5 dB(A)).
Each test session consisted of 50 trials, with a startle stimulus of 115 ± 5 dB(A)
mixed-frequency ‘‘noise’’ burst set to 20-ms duration and 8-s intertrial interval.
Startle response data were analyzed in ﬁve blocks of 10 trials each to evaluate
intrasession habituation. Concurrent with the onset of the startle-eliciting
stimulus, force was measured using an accelerometer attached to the bottom of
each enclosure, with the output collected every millisecond for 100 ms. Startle
response measurements obtained for each trial were the maximum response
amplitude (MAX), measured in newtons (N), and the latency (msec) to MAX
(TMAX). TMAX was used as a reference to verify appropriate instrument
measurement of the primary startle response and was not statistically analyzed.
Biel water maze. Swimming performance and learning and memory were
assessed in three phases over a 7-day period using a water-ﬁlled eight-unit
T-maze similar to that described by Biel (1940). Animals were placed in the
maze and were required to traverse the maze and escape by locating a platform
that was hidden 2 cm beneath the surface of the water.
Phase 1 was an evaluation of swimming ability and motivation to escape
from the maze and was performed in four consecutive trials on day 1 by
measuring the time required for the rat to swim the length of a 4-foot straight
channel. Animals were allowed 2 min to complete each trial. At the end of each
trial, the animal was immediately placed at the starting position for another trial
until all four trials were complete.
Phase 2 evaluated sequential learning on days 2–6. Animals were allowed
two trials per day for 2 days to solve the maze in path A. Animals were then
allowed two trials per day for 3 consecutive days to solve the maze in path B,
which was the reverse of path A. If the animal failed to escape after 3 min, it
was placed on the platform for 20 s and then removed from the maze until
subsequent trials were conducted (minimum intertrial interval of 1 h).
Phase 3 (day 7) tested the animal for its memory to solve the maze when
challenged in path A. The testing was conducted in two trials on 1 day as
described for phase 2.
For the learning and memory phases (i.e., phases 2 and 3), the number of
errors for each trial was recorded and analyzed over successive trials. An error
was deﬁned as any instance when an animal deviated from the correct channel
with all four feet.
F0 necropsy and organ weights. A gross pathological examination of all
F0 females was carried out. The maternal liver and kidneys were weighed
and examined microscopically. Offspring of dams found dead or euthanized
in extremis prior to weaning were subjected to a gross pathological
examination. Offspring of a litter failing to meet the sex ratio criteria were
euthanized and similarly subjected to a gross pathological examination.
F1 offspring necropsy. A gross pathological examination of stillborn pups
and pups dying between birth and PND 72 was conducted. All pups not used
for neuropathological evaluation were similarly examined. Offspring that were
culled on PND 4 were not examined.
Neuropathology. Pups (one per sex per litter) selected for neuropathology
on PNDs 21 and 72 were perfused in situ with ﬁxative (4% paraformaldehyde/
1.4% glutaraldehyde), and the brain was processed for microscopic
examination following at least 36 h in ﬁxative; on PND 72, additional central
nervous system (CNS) and peripheral nervous system (PNS) tissues were
processed. Before processing for microscopic assessments, macroscopic
evaluations including whole brain weight, as well as brain length and width,
were recorded. Additionally, any abnormal coloration or lesions of the brain
were recorded. Microscopic neuropathological examination was performed on
one male or female per litter for a total of 10 pups per sex per dose group from
all groups with the two cohorts as equally represented as possible. In addition,
for PND 72 evaluations, neuropathological examinations were performed on
any pup that was not selected in the original 10 pups per sex per dose group but
showed potential treatment-related effects on neurobehavioral observations or
measurements. The data for these additional pups were not included in the
statistical analyses.
For microscopic evaluation, the CNS tissues were embedded in parafﬁn and
PNS tissues in plastic (glycol methacrylate). Histopathological evaluation was
conducted on tissues stained with hematoxylin and eosin. For animals
euthanized on PNDs 21 and 72, the following brain regions were examined:
olfactory bulbs, cerebral cortex, hippocampus, basal ganglia, thalamus,
hypothalamus, midbrain, cerebellum, pons, and medulla oblongata. The spinal
cord was examined at cervical swellings C3-C7 and at lumbar swellings T13-L4
for the animals euthanized on PND 72. Also, for the animals euthanized on
PND 72, the following PNS tissues were examined: cervical dorsal root ﬁbers
and ganglia (C3-C7); cervical ventral root ﬁbers (C3-C7); eyes with retinae;
lumbar dorsal root ﬁbers and ganglia (T13-L4); trigeminal ganglia/nerves;
lumbar ventral root ﬁbers (T13-L4); optic nerves; peroneal, sciatic, sural, and
tibial nerves; and skeletal muscle (gastrocnemius).
TABLE 3
Parameters for DCO
Arousal
Backing
a
Bizarre/stereotypic behavior
Convulsions/tremors
Ease of handling animal in hand
Ease of removal from cage
Eye color
a,b
Eye prominence
a,b
Fur appearance
a,b
Gait
a
General body posture
Grooming
a,b
Lacrimation/chromodacryorrhea
Mobility
a
Mucous membranes and skin (color)
Muscle tone
Palpebral closure
a,b
Red/crusty deposits
Piloerection
a,b
Pupillary response
a,b
Respiratory rate/character
Salivation
Urination/defecation
aNot assessed for PND 4 pups due to stage of development.
bNot assessed for PND 11 pups due to stage of development.
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selected PNDs 21 and 72 offspring were conducted using the Pax-It (MIS, Inc.,
Franklin Park, IL) image-capturing computer system and software (version
4.0). Speciﬁc levels analyzed were deﬁned as follows: level 1 was a coronal
section of rostral cerebrum, including caudoputamen; level 3 was a coronal
section of mid-cerebrum (cerebral cortex, hippocampal formation, thalamus,
etc.); and level 5 was a midsagittal section of cerebellum and pons. Levels 1, 3,
and 5 corresponded to plates 11, 33, and 79, respectively, in the reference text
(Paxinos and Watson, 1998). Measurements on levels 1 and 3 were bilateral,
when possible, and were averaged for each animal. Measurements on level 5
were not averaged since the other halves of these tissues were sectioned
transversely to enable visualization of cerebellar nuclei. Measurements were
made on homologous sections to ensure that the dimensions of the regions were
comparable.
Statistical Analyses
The statistical methods employed in this study were based on recent
recommendations from an International Life Sciences Institute (ILSI) Expert
Panel that reported on the analyses of neurodevelopmental end points in DNT
studies (Holson et al., 2008). Pairwise comparisons, rather than trend analyses,
were conducted so that potential effects at the low-dose levels would not be
overlooked.
Data from nonpregnant F0 animals were excluded from statistical analyses.
With the exception of adult measurements (body weights and neurobehavioral
assessments) on the F1 generation, when a statistical analysis included
measurements on multiple offspring from the same litter, the litter was used
as the experimental unit and accounted for in the statistical analysis. Statistical
analyses were generated from the WIL Toxicology Data Management System,
or conducted in SAS version 9.1.
A number of end points were evaluated using different statistical models
(Table 4). Details of the analysis models and the statistical decision-making
process are included in the Supplementary data.
RESULTS
Maternal (F0) Observations
Fate,clinicalobservations,andreproductiveendpoints. There
were no treatment-related effects on pregnancy rates; the values
were >95% in all groups. One female each in the control and
0.15-ppm groups were nongravid. In the 2250-ppm group, one
female was found dead during the process of parturition on LD
0. There were no indications of the cause of death, and this
single death was not attributed to BPA exposure. All other
females survived to the scheduled necropsy. No treatment-
related clinical ﬁndings were noted in the females at the daily
examinations or during DCO at GDs 10 and 15, or LDs 10 and
21. No treatment-related effects were noted on mean gestation
lengths or on parturition at any exposure level.
Gestational body weight and feed consumption. Treatment-
related lower mean body weight gains (p < 0.05) were noted in
the 750- and 2250-ppm groups during the ﬁrst week of dietary
exposure (GDs 0–7; Table 5). Mean body weight gains in these
groups were similar to the control group during GDs 7–14 and
14–20. As a result of the initial reductions, mean body weight
gains in the 750- and 2250-ppm groups were statistically
signiﬁcantly lower (9.5 and 22.5%, respectively) compared with
the control group throughout gestation (GDs 0–20; Table 5). In
addition, mean body weights were 4.7–5.2% and 8.6–10.7%
lower (p < 0.05) than control in these same respective groups
during GDs 3–20 (Fig. 1). Mean body weights and body weight
gains in the 0.15-, 1.5-, and 75-ppm groups were unaffected by
BPA exposure during gestation (Fig. 1, Table 5).
Mean feed consumption in the 750- and 2250-ppm groups
was lower than in the control group (p < 0.05) and
TABLE 4
Summary of Statistical Tests
Analysis End points
ANOVA (1) F0 maternal body weight gain GDs 0–20; gestation
length
a; former implantation sites
a; unaccounted-for
sites; number of pups born
a; live litter size
a; DCO
(continuous data)
a
ANOVA (2) F1 morphometric measurements from the neocortical,
hippocampal, and cerebellar areas (dependent on
the outcome of the brain weight, length, and width
analysis)
b
ANOVA (3) F1 PPS; F1 vaginal separation
ANOVA (4) Preculling pup body weight gain; F1 surface righting
ANCOVA (5) F0 organ weights
RANOVA (6) F0 maternal gestation and lactation body weights, body
weight gains, and feed consumption
RANOVA (7) F1 adult body weights; F1 motor activity within
(total counts from six 10-min intervals) session
PND 61; F1 auditory startle response (MAX) PND 60;
F1 Biel water maze (number of errors) PND 62
RANOVA (8) Pre- and postculling pup body weights; postculling pup
body weight gain; pup motor activity within (total
counts from six 10-min intervals) and across
(cumulative total count) sessions PNDs 13, 17, and
21; pup auditory startle response (MAX) PND 20;
pup Biel water maze (number of errors) PND 22
MANOVA (9) F1 brain weight, brain length, and brain width;
F1 morphometric measurements from the neocortical,
hippocampal, and cerebellar areas (dependent on the
outcome of the brain weight, length, and width
analysis)
b
K-W (10) Pup viability; males per litter
Fisher (11) DCO (scalar and descriptive data)
Note. ANCOVA, analysis of covariance; RANOVA, repeated measures
ANOVA; MANOVA, multivariate ANOVA; K-W, Kruskal-Wallis test; Fisher,
Fisher’s exact test. Factors in the models included treatment group (TRT;
1–10), sex (2, 4, 7–9), time (6–8), cohort (blocking factor; 1–3, 5–9), and litter
(random effect; 3, 4, 8). Interaction terms included TRT 3 Sex (2, 4, 7–9),
TRT 3 Time (6–8), and TRT 3 Sex 3 Time (7, 8). For the ANCOVA (5),
ﬁnal body weight was the covariate. Individual group comparisons with the
control were made by way of Dunnett’s test (1–8), linear contrasts (9), or
Dunn’s test (10).
aEnd points analyzed using the WIL Toxicology Data Management System
did not include cohort as a blocking factor.
bIf there was a statistically signiﬁcant treatment (TRT) effect for brain
weight, brain length, and brain width (indicating an overall change in brain
size), the analysis of microscopic examinations was conducted by MANOVA.
Otherwise, the analysis of microscopic examinations was conducted by
ANOVA (2).
DEVELOPMENTAL NEUROTOXICITY BPA RAT STUDY 171corresponded to the lower mean body weight gain during the
ﬁrst week (GDs 0–7) of test diet exposure. Mean feed
consumption in the 0.15-, 1.5-, and 75-ppm groups was
unaffected by BPA exposure during gestation (Supplementary
table 1).
Lactational body weight and feed consumption. Lacta-
tional body weight data for the dams are presented in Figure 1.
As a result of the initial reductions in mean body weight gains
during GDs 0–7, the mean body weights during LDs 1–17 in
the 750- and 2250-ppm groups ranged from 3.8 to 5.2% and
8.1 to 9.6% lower, respectively, compared with the control
group. Mean body weight gains in all groups were unaffected
by BPA exposure during lactation. Mean feed consumption
in the 0.15-, 1.5-, 75-, 750-, and 2250-ppm groups was
unaffected by BPA exposure during lactation (Supplementary
table 2).
BPA intake. The mean doses of BPA consumed by the
dams are presented in Table 6. Values during the entire
lactation period for all groups were elevated as feed
consumption increased to support milk production. Feed
consumption is also known to increase after LD 14 due to
self-feeding of the pups.
Maternal necropsy. No treatment-related gross ﬁndings or
effects on the number of former implantation sites and the
number of unaccounted-for sites were observed. There were no
treatment-related alterations in mean kidney or liver weights in
F0 females at any exposure level when analyzed with ﬁnal
body weight as the covariate. There were no microscopic
alterations associated with BPA exposure in the livers or
kidneys of any F0 females at any exposure level.
Offspring (F1) Observations
F1 fate and clinical observations. The mean number of
pups born, live litter size, percentage of males per litter at birth,
and postnatal survival between birth and weaning were
unaffected at all BPA exposure levels (Supplementary table
3a–d). No daily clinical observations noted for F1 pups were
attributed to BPA exposure (data not shown).
F1 body weights and developmental landmarks. Mean
male and female pup body weight and preweaning body weight
gain data are provided in Tables 7 and 8, respectively. Mean
male and female pup body weight gains in the 750- and 2250-
ppm groups were similar to the control group during PNDs 1–7,
lower than in the control group (p < 0.05) during PNDs 7–14,
and similar to the control group during PNDs 14–21. Because
of the lower body weight gains during PNDs 7–14, mean male
and female pup body weights in the 750-ppm group were lower
(p < 0.05) than in the controls (4.7–5.6%) on PND 14 and/or 17
before recovering by PND 21. Mean male and female body
weights in the 2250-ppm group were lower (p < 0.05) than in
the controls (4.8–8.3%) beginning on PND 11 and continuing
through the end of the preweaning period (PND 21).
Mean pup body weights and body weight changes in the
0.15-, 1.5-, and 75-ppm group males and females were
unaffected by BPA exposure throughout the postnatal period.
TABLE 5
Gestational Body Weight Gain (g) for F0 Rats Exposed to BPA
GD
BPA dietary concentration (ppm)
0 0.15 1.5 75 750 2250
0–7 31 34 32 31 21* 2*
7–14 38 39 40 34 36 35
14–20 78 78 79 78 75 77
0–20 147 151 151 143 133* 114*
Note. n ¼ 23–24.
*p < 0.05.
FIG. 1. F0 female body weights during the gestational and lactational
periods. Ordinate is body weights (mean gram ± SEM); abscissa is days. ‘‘*’’
indicates that the mean body weight is statistically signiﬁcantly different from
that of the control group using Dunnett’s test (p < 0.05).
TABLE 6
Calculated Doses of BPA
BPA dietary
concentration
(ppm)
Mean (range of biweekly means;
mg BPA/kg/day)
Gestation Lactation
0.15 0.01 (0.01–0.01) 0.03 (0.02–0.03)
1.5 0.12 (0.10–0.13) 0.25 (0.18–0.31)
75 5.85 (5.32–6.43) 13.1 (9.31–16.1)
750 56.4 (51.1–60.9) 129 (86.9–158)
2250 164 (93.8–196) 410 (288–527)
172 STUMP ET AL.Statistically signiﬁcant increases and decreases in body weight
in the 0.15- and 75-ppm dose groups were not considered
treatment related because no dose-related trends were apparent
and no consistent temporal trends were observed. At 75 ppm,
there were slightly fewer pups per litter at birth (mean 14.9
pups per litter vs. 15.7 pups per litter for the control group;
Supplementary table 3a), and the mean gestation length was
0.3 days longer than that of the controls (Supplementary
table 4); both of these factors may have contributed to the
greater pup body weights in this group. There were no other
statistically signiﬁcant differences from the control group.
Mean postweaning offspring body weights and body weight
gains were unaffected by BPA at all levels of exposure. Mean
female body weight in the 2250-ppm group was slightly lower
(8.0%) than in the control on PND 28 due to reduced mean
body weight gain during the preweaning period. However, the
difference from the control group was not statistically
signiﬁcant (analyzed by sexes combined), and the mean female
body weights in this group were similar to the control group
throughout the remainder of the postweaning period (PNDs
35–70).
There were no treatment-related effects on the age to attain
surface righting response, PPS, or VP at any dose (Supple-
mentary table 5).
Neurobehavioral assessments. No treatment-related effects
were noted when DCO data were evaluated for PNDs 4, 11,
21, 35, 45, and 60. Incidental ﬁndings in the BPA-exposed
groups included the following: on PND 11 only, a total of six
pups (two animals from the 750-ppm group and four from the
2250-ppm group) exhibited irregular jerking movements of
limbs, head, and/or body and/or jumping with all four feet in
the air. These clonic movements were recorded as ‘‘con-
vulsions’’ and/or ‘‘popcorn seizures.’’ The incidence of these
ﬁndings was not statistically signiﬁcant (Supplementary table
6a–b) and occurred during the same period where statistically
signiﬁcantly reduced mean pup body weight gains were noted
(PNDs 7–14) in the 750- and 2250-ppm groups (Table 8).
These ﬁndings were not observed at any other age. For these
six animals, there were no remarkable ﬁndings in the other end
points examined as part of the detailed clinical observations.
The incidence of these ﬁndings in the historical control
database at PND 11 is 2 of 244 females and 0 of 243 males.
Since the incidence of these ﬁndings in the present study was
greater than the historical control incidence, a focused follow-
up study was conducted at 2250 ppm BPA to determine
reproducibility and, if appropriate, to further characterize these
ﬁndings. Similar effects were noted on body weight in the
TABLE 7
Body Weight (g) of F1 Offspring of F0 Rats Exposed to BPA
PND
BPA dietary concentration (ppm)
0 0.15 1.5 75 750 2250
Males
1 7.0 7.2 7.0 7.4 7.1 6.8
4 9.5 9.8 9.5 10.2* 9.6 9.0
4
a 9.4 9.8 9.6 10.2* 9.7 9.0
7 15.4 16.0 15.7 16.6* 15.6 14.8
11 25.1 25.8 25.0 26.1* 24.1 23.4
14 33.2 33.7 32.9 34.0 31.6* 31.1*
17 40.6 41.6 40.5 41.6 38.7* 38.1*
21 52.2 54.3* 52.5 54.4* 50.2 49.7*
28 94 97 94 96 93 91
35 156 161 157 158 154 149
42 223 230 224 227 221 216
49 283 291 286 290 283 276
56 341 355 345 352 344 338
63 380 395 387 394 383 376
70 410 423 416 425 414 404
72 422 435 427 436 426 417
Females
1 6.6 6.8 6.5 7.0 6.8 6.4
4 8.9 9.3 8.9 9.6* 9.2 8.4*
4
a 9.0 9.3 8.9 9.6 9.2 8.4
7 14.7 15.2 14.7 15.4 14.8 13.9
11 24.1 24.6 23.7 24.6 23.3 22.1*
14 32.0 32.6 31.6 32.2 30.2* 29.6*
17 39.1 40.0 39.1 39.5 37.3 36.2*
21 50.2 51.7 50.0 51.1 48.1 46.8*
28 87 89 86 85 85 80
35 132 138 132 131 130 126
42 169 178 170 169 166 164
49 194 204 196 195 191 192
56 218 229 218 221 216 215
63 238 253 239 240 234 232
70 251 265 252 253 250 245
72 256 272 256 257 255 253
Note. n ¼ 21–24. Statistics performed by sex through PND 21 only.
aAfter culling.
*p < 0.05.
TABLE 8
Preweaning Body Weight Gain (g) of F1 Offspring of F0 Rats
Exposed to BPA
PND
BPA dietary concentration (ppm)
0 0.15 1.5 75 750 2250
Males
1–4 2.5 2.6 2.6 2.8 2.5 2.1
4–7 6.0 6.1 6.2 6.5 6.0 5.8
7–14 17.7 17.7 17.2 17.4 15.9* 16.3*
14–21 19.0 20.6* 19.6 20.3* 18.7 18.6
Females
1–4 2.3 2.5 2.3 2.7 2.4 2.0
4–7 5.8 5.9 5.9 6.0 5.7 5.5
7–14 17.2 17.5 16.8 16.8 15.4* 15.6*
14–21 18.3 19.1 18.3 18.8 17.9 17.3
Note. n ¼ 23–24. Statistics performed by sex through PND 21 only.
Statistics were conducted on combined sexes following weaning (PND 28 on).
*p < 0.05.
DEVELOPMENTAL NEUROTOXICITY BPA RAT STUDY 173dams and offspring; however, no clonic movements were
observed on PND 11 in this robust follow-up study; therefore,
the initial observations were not considered to be treatment
related (details of materials and methods and results in
Supplementary data [table 7a–b]).
Motor activity (PNDs 13, 17, 21, and 61). Motor activity
data for males and females are presented in Figure 2a–c. Motor
activity was unaffected by BPA exposure at any dietary
concentration. The pattern of activity over the course of the test
session at each age and the overall 60-min test session values
were comparable with the concurrent control (Supplementary
table 8a–c).
Auditory startle (PNDs 20 and 60). Auditory startle
response data are shown in Figure 3a–d. The auditory startle
FIG. 2. Mean (±SEM) 1-h session total activity counts (ambulatory and ﬁne movements) for F1 offspring (combined sexes) motor activity testing on PNDs 13,
17, and 21 (A) and for F1 males and females separately on PND 61 (B and C). There were no statistically signiﬁcant effects obtained in the repeated measures
ANOVA (RANOVA) for total activity counts on PNDs 13, 17, and 21, or PND 61. The ontogeny (PNDs 13, 17, and 21) data for males and females were
combined, to enhance statistical power, and are presented as combined sexes because neither the treatment by sex nor the treatment by sex by time interaction was
statistically signiﬁcant. The data for PND 61 are presented separately for males and females because the overall RANOVA revealed a treatment by sex by time
interaction.
174 STUMP ET AL.response habituation paradigm was conducted for F1 animals
evaluated on PND 20 and for the same animals on PND 60. No
effects were noted on auditory startle response amplitude or in
the pattern of habituation over the 50-trial test session at either
age (Supplementary table 9a–c).
Learning and memory: Biel maze swimming trials (PNDs 22
and 62). Biel maze error data are provided in Figure 4a–d.
Swimming ability on day 1 of the Biel maze assessment (PND
22 or 62) was similar in all groups (Supplementary table 10a–f).
There were no treatment-related effects on the number of errors
committed by males or females at any dose level, at either age
(Fig. 4). For females on PND 22, the overall mean number of
errors committed in the 0.15- and 2250-ppm groups was lower
(p < 0.05) than in the control group for path B (trials 5–10),
which was likely due to an atypically high error rate in the
PND 22 female control group in path B (i.e., outside historical
control range). On PND 62, the overall mean number of errors
committed by males in the 0.15-ppm group for path A (trials
1–4) was higher (p < 0.05) than the control group mean;
however, the mean value for the control group was lower than
the historical control mean values for trials 3 and 4, and
performance of the 0.15-ppm males was similar to that of
controls on path B. Last, the mean number of errors on PND 62
for the combined males and females in the 1.5-ppm group was
higher than in the control group for trial 7 only, whereas the
number of errors was similar to controls for all other trials in
path B. Thus, all statistically signiﬁcant differences noted were
considered spurious and not BPA related because they did not
occur consistently between or within testing periods, did not
demonstrate any evidence of a dose-related trend, and/or were
associated with atypical control responses (Supplementary
table 10a–f).
F1 offspring necropsy. No gross necropsy ﬁndings that
could be attributed to BPA exposure were noted at any dose.
During the postweaning period (PNDs 21–72), one female in
the control group and three males in the 1.5-ppm group were
found dead or euthanized in extremis. No remarkable gross
ﬁndings were noted for any of these animals at necropsy.
Neuropathology. No treatment-related gross ﬁndings were
observed in the brain at PND 21 or in the brain and spinal cord
at PND 72 in F1 animals. There were no differences from
control animals with respect to treatment-related effects on
brain measurements (weight, gross length or width, or
microscopic measurements) on PND 21 or 72, and there were
no effects on histopathological or morphometric alterations in
the brain at PND 21 or 72 at any BPA exposure level for males
or females (Table 9). In addition, there were no treatment-
related microscopic alterations in the brain on PND 21 or in
central or peripheral nervous system tissues at PND 72 at any
BPA exposure level. Five pups (two males and one female in
the 0.15-ppm group, one female in the 75-ppm group, and one
male in the 2250-ppm group) each had a unilateral nest of
embryonal cells in the lateral caudoputamen. A third male in
the 0.15-ppm group had nests of embryonal cells at the lateral
aspect of the caudate nucleus adjacent to the external capsule.
These nests of embryonal cells most closely resembled the cells
of the normal subependymal zone and occurred in the lateral
caudoputamen close to the location of the lateral ventricles.
FIG. 3. Mean (±SEM) maximum startle response amplitude in newtons
(MAX) across 10-trial blocks of each 50-trial testing session for F1 offspring
(combined sexes) on PND 20 (A) and PND 60 (B). There were no statistically
signiﬁcant effects obtained in the repeated measures ANOVA for maximum
response amplitude on PND 20 or 60. The data for males and females were
combined, to enhance statistical power, and are presented as combined sexes
because neither the treatment by sex nor the treatment by sex by trial interaction
was statistically signiﬁcant.
DEVELOPMENTAL NEUROTOXICITY BPA RAT STUDY 175FIG. 4. Mean(±SEM)numberoferrorsacross12trialsintheBielwatermazetaskformaleandfemaleF1offspringseparatelyonPND22(males:A,females:B)and
PND62(males:C,females:D).AtPND22,thenumberoferrors(i.e.,animaldeviatesfromthecorrectchannelwithallfourfeet)inthe0.15-and2250-ppmgroupfemales
wasstatisticallysigniﬁcantlylowerthaninthecontrolgroupacrossthecombinedtrials5–10,pathB(Fig.B);andatPND62,thenumberoferrorsinthe0. 15 -p pmgr o up
maleswasstatisticallysigniﬁcantlyhigherthantheincontrolgroupacrossthecombinedtrials1–4,pathA(Fig.C).Inbothcases,becausethetreatmentbytrialinteraction
was not statistically signiﬁcant, trials were not individually analyzed. When analyzed by sex, there were no additional statistically signiﬁcant effects obtained in the
repeated measures ANOVA (RANOVA) for meannumber of errors during the 7-day learningand memory test. Whenthe sexes were combined for analysis atPND 62,
a treatment bytrialinteractionrevealed that the mean number of errorsinthe 1.5-ppm groupwas statisticallysigniﬁcantlyhigherthaninthe control groupon trial7 only
(data not shown). The PND 22 data are presented separately for males and females because the overall RANOVA revealed a treatment-by-sex interaction (trials 5–10
only).ThePND62dataarepresentedseparatelyformalesandfemalesbecausetheoverallRANOVArevealedatreatmentbysexbytrialinteraction(trials1–4only).The
data frommalesandfemaleswere combined(combineddatanotshown),toenhancestatisticalpower,onPND22(trials1–4and11–12)andonPND62(trials5–10and
11–12) because neither the treatment by sex nor the treatment by sex by trial interaction was statistically signiﬁcant. Trial indicates the session trial. Trials 1–4 were
conducted in the forward direction (path A), trials 5–10 were conducted in the reverse direction (path B; opposite of path A), and trials 11–12 were conducted in the
forward direction (path A). Trials 1–10 tested learning and trials 11–12 probed for memory. *p < 0.05, Dunnett’s test.
176 STUMP ET AL.Consistent with the known process of cell migration (Paretto
et al., 1999), these nests were most likely migrating cells that
did not complete their migration or undergo programmed cell
death by PND 21. The historical control data for the laboratory
indicate that ‘‘ectopic tissue’’ in the basal ganglia of the brain
of PND 21 rats similar to the embryonal cell nests diagnosed in
the present study was observed in one male and one female (of
70 and 69, respectively) control rats. Because of the occurrence
of this ﬁnding in control rats of both sexes, the lack of a dose
response, and unilateral nature of the ﬁnding, these observa-
tions were considered to be incidental rather than treatment
related. One female in the 750-ppm group had mild cortical
dysplasia that primarily involved the molecular/plexiform layer
of the cerebral cortex. Nests of cells either extended up into this
normally hypocellular superﬁcial layer (within the level 1
section) or this layer was unusually expanded/focally wider
within the level 4 section. The presence of this dysplasia in
only one pup and lack of a dose-response relationship indicated
that it was a spontaneous lesion rather than a treatment-related
effect.
DISCUSSION
The potential effects of BPA on neurodevelopment following
exposure of rodents during gestation and lactation have been
evaluated in several studies; an assessment of these studies has
indicated that there were no consistent patterns of effects across
studies and end points (Chapin et al., 2008). Since BPA has
weak estrogen-like properties, it has been hypothesized that
BPA may affect neurodevelopment via an estrogenic mode of
action. A large number of studies have been reported in the
published literature that have examined the developmental
neurotoxicity potential of BPA. These studies have been
summarized by the EU (2010). Conﬁdence in the reliability of
these studies is low because of the limitations in study design
and reporting of all the available studies (EU, 2010).
The DNT test guideline was selected as a robust study
design that is widely used to examine the potential of chemicals
to affect neurodevelopment. Additional design elements were
considered for inclusion in the study to address concerns over
reported disruption of sexual differentiation of the brain and
sexually dimorphic mating behaviors (e.g., lordosis). However,
these end points were not selected for inclusion in the study
because none has undergone the elaborate and extensive
process involving multiple laboratories and reference chem-
icals, with ultimate consideration for relevance to human health
required for validation (Balls et al., 1994; Makris et al., 2009;
Moser, 1997). In addition, the multigeneration reproduction
studies of BPA would have identiﬁed any substantive effect on
mating behaviors through the alteration of some reproductive
end points (e.g., time to mating, mating index, fertility index);
these end points were clearly unaffected by BPA at any dose
(Ema et al., 2001; Tyl et al., 2002, 2008d).
The present study used the Sprague-Dawley rat, which has
been shown to be responsive to BPA exposure as evidenced by
reduced body weight and organ weights in adults and
offspring, histopathological effects in liver and kidney in
adults, and delayed VP and preputial separation in offspring
secondary to reduced body weights (Tyl et al., 2002). The
Sprague-Dawley rat has also been shown to be responsive to
orally administered 17-b-estradiol (Biegel et al., 1998; Tyl
et al., 2006). Furthermore, strain differences in response to
estrogens in rats vary across tissues, so no strain can be
considered more sensitive than another (Chapin et al., 2008;
Howdeshell et al., 2008, Ryan et al., 2010). Moreover, the
Sprague-Dawley strain was selected for this study because it
has been used extensively for DNT studies at the testing
laboratory, with demonstrated sensitivity of the various tests to
perturbation using appropriate positive controls.
Consideration was also given to the potential inclusion of
a group treated with a steroidal estrogen in the study design for
comparison with BPA-treated groups as some researchers have
reported observing slight differences in motor activity measure-
ments between sexes in rats (Tyl et al., 2008a). However, these
differences may depend on the device used for measurement,
and even reproducibility across studies within a given
laboratory has been inconsistent (Tyl et al., 2008a). In addition,
there are no data from studies conducted by the DNT
guidelines to indicate whether the behavioral and neuro-
developmental end points in the DNT study would be sensitive
to steroidal estrogens (Ferguson et al.,2 0 0 0 ), and estrogen is
not among the list of positive control agents published by the
ILSI Research Foundation (Crofton et al., 2008). Thus, there
was insufﬁcient support from the literature to adopt the use of
a steroidal estrogen as a ‘‘positive control’’ for the end points
measured in this study. More importantly, there was no need
for a concurrent positive control group as data were developed
in the testing laboratory using known positive control
chemicals in Sprague-Dawley rats to establish the reliability
and sensitivity of the neurotoxicology test methods, under the
conditions used for this study, including DCO, motor activity,
auditory startle, learning and memory (Biel water maze), and
morphometry.
The use of Purina Certiﬁed 5002 Rodent Diet has been
challenged in studies examining estrogen-sensitive end points
due to its phytoestrogen content. In the present study, the
phytoestrogen level of the lot of diet used was 312 ppm in total
aglycone units. The total phytoestrogen content as genistein
equivalents was 290 ppm, which is below the recommended
maximum of 350 ppm speciﬁed for the uterotrophic bioassay in
the recently ﬁnalized OECD (2007b) Test Guideline 440.
Further, this diet has been used in studies showing responses to
a steroidal estrogen (17-b-estradiol; Biegel et al.,1 9 9 8 ; Tyl
et al., 2006, 2008b,c) and BPA (Tyl et al., 2002, 2008d).
Therefore, the phytoestrogen content of the diet used in this
study would not be expected to inﬂuence the outcome.
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F1 Male and Female Offspring Whole Brain Measurements and Morphometry
Measurement
BPA dietary concentration (ppm)
0 0.15 1.5 75 750 2250
Male
PND 21
Terminal body weight (g) 52 ± 6.2 (23) 55 ± 6.0 (23) 53 ± 5.8 (24) 55 ± 5.1 (22) 50 ± 7.9 (22) 50 ± 5.6 (23)
Relative brain weight
(g/100 g body weight)
3.14 ± 0.29 (23) 3.08 ± 0.35 (23) 3.10 ± 0.23 (24) 3.02 ± 0.27 (22) 3.26 ± 0.48 (22) 3.31 ± 0.32 (23)
Brain length (mm) 18.2 ± 0.4 (23) 18.3 ± 0.4 (23) 18.2 ± 0.4 (24) 18.3 ± 0.4 (22) 18.2 ± 0.4 (22) 18.2 ± 0.4 (23)
Brain width (mm) 14.6 ± 0.3 (23) 14.8 ± 0.3 (23) 14.6 ± 0.3 (24) 14.7 ± 0.3 (22) 14.6 ± 0.4 (22) 14.7 ± 0.3 (23)
Morphometric parameters (mm)
Level 1
Ht of hemisphere 0.72 ± 0.03 (10) 0.73 ± 0.04 (10) 0.73 ± 0.03 (10) 0.72 ± 0.03 (10) 0.72 ± 0.02 (10) 0.71 ± 0.01 (10)
Vertical thickness of cortex 0.18 ± 0.01 (9) 0.18 ± 0.01 (10) 0.18 ± 0.02 (10) 0.18 ± 0.01 (10) 0.18 ± 0.01 (10) 0.18 ± 0.01 (10)
Level 3
Radial thickness of cortex 0.16 ± 0.01 (10) 0.16 ± 0.01 (10) 0.15 ± 0.01 (10) 0.15 ± 0.01 (10) 0.15 ± 0.01 (10) 0.16 ± 0.01 (10)
Vertical ht between
pyramidal neuron layersþ
0.09 ± 0.01 (10) 0.09 ± 0.00 (10) 0.09 ± 0.01 (10) 0.09 ± 0.01 (10) 0.09 ± 0.01 (10) 0.09 ± 0.00 (10)
Vertical ht of dentate hilus 0.05 ± 0.01 (10) 0.05 ± 0.00 (10) 0.05 ± 0.00 (10) 0.05 ± 0.00 (10) 0.05 ± 0.00 (10) 0.05 ± 0.00 (10)
Length of ventral limb of
dentate hilus
0.14 ± 0.02 (9) 0.14 ± 0.01 (9) 0.15 ± 0.01 (10) 0.14 ± 0.02 (10) 0.14 ± 0.01 (10) 0.15 ± 0.01 (10)
Level 5
Vertical ht of cerebellum 0.48 ± 0.02 (10) 0.48 ± 0.03 (10) 0.48 ± 0.04 (10) 0.49 ± 0.03 (10) 0.48 ± 0.02 (10) 0.47 ± 0.03 (10)
Thickness of the base of
cerebellar lobule 9
0.06 ± 0.00 (10) 0.06 ± 0.01 (10) 0.06 ± 0.01 (10) 0.06 ± 0.01 (10) 0.06 ± 0.00 (10) 0.06 ± 0.00 (10)
PND 72
Terminal body weight (g) 422 ± 32.0 (23) 435 ± 40.2 (23) 427 ± 25.4 (23) 436 ± 40.1 (22) 426 ± 39.9 (21) 417 ± 44.5 (23)
Relative brain weight
(g/100 g body weight)
0.52 ± 0.03 (23) 0.52 ± 0.05 (23) 0.52 ± 0.02 (23) 0.50 ± 0.04 (22) 0.51 ± 0.04 (21) 0.52 ± 0.05 (23)
Brain length (mm) 21.1 ± 0.5 (23) 21.0 ± 0.5 (23) 21.1 ± 0.4 (23) 20.9 ± 0.4 (22) 21.0 ± 0.4 (21) 21.0 ± 0.4 (23)
Brain width (mm) 15.6 ± 0.3 (23) 15.7 ± 0.3 (23) 15.6 ± 0.3 (23) 15.6 ± 0.2 (22) 15.6 ± 0.3 (21) 15.6 ± 0.4 (23)
Morphometric parameters (mm)
Level 1
Ht of hemisphere 0.73 ± 0.03 (10) 0.73 ± 0.04 (10) 0.71 ± 0.03 (10) 0.73 ± 0.03 (10) 0.72 ± 0.04 (10) 0.71 ± 0.03 (10)
Vertical thickness of cortex 0.18 ± 0.01 (10) 0.18 ± 0.01 (10) 0.18 ± 0.01 (10) 0.18 ± 0.01 (10) 0.18 ± 0.01 (10) 0.18 ± 0.01 (10)
Level 3
Radial thickness of cortex 0.17 ± 0.01 (10) 0.18 ± 0.01 (10) 0.16 ± 0.01 (10) 0.17 ± 0.01 (10) 0.17 ± 0.01 (10) 0.16 ± 0.01 (10)
Vertical ht between pyramidal
neuron layersþ
0.10 ± 0.00 (10) 0.10 ± 0.01 (10) 0.10 ± 0.01 (10) 0.10 ± 0.01 (10) 0.09 ± 0.01 (10) 0.10 ± 0.01 (10)
Vertical ht of dentate hilus 0.05 ± 0.00 (9) 0.05 ± 0.00 (10) 0.05 ± 0.00 (9) 0.05 ± 0.00 (9) 0.05 ± 0.00 (10) 0.05 ± 0.00 (9)
Length of ventral limb of
dentate hilus
0.15 ± 0.01 (10) 0.15 ± 0.01 (10) 0.14 ± 0.01 (10) 0.14 ± 0.01 (10) 0.14 ± 0.02 (10) 0.15 ± 0.02 (10)
Level 5
Vertical ht of cerebellum 0.53 ± 0.03 (10) 0.53 ± 0.02 (10) 0.51 ± 0.02 (10) 0.52 ± 0.03 (10) 0.51 ± 0.03 (10) 0.51 ± 0.02 (10)
Thickness of the base of
cerebellar lobule 9
0.08 ± 0.01 (10) 0.07 ± 0.01 (10) 0.07 ± 0.01 (10) 0.07 ± 0.01 (10) 0.07 ± 0.01 (10) 0.08 ± 0.00 (10)
Female
PND 21
Terminal body weight (g) 51 ± 4.1 (23) 52 ± 5.2 (23) 51 ± 5.6 (23) 52 ± 6.9 (22) 47 ± 8.1 (22) 48 ± 5.0 (23)
Relative brain weight
(g/100 g body weight)
3.07 ± 0.20 (23) 3.13 ± 0.26 (23) 3.11 ± 0.32 (23) 3.09 ± 0.40 (22) 3.36 ± 0.53 (22) 3.28 ± 0.29 (23)
Brain length (mm) 18.0 ± 0.3 (23) 18.1 ± 0.3 (23) 18.0 ± 0.4 (23) 17.8 ± 0.4 (22) 17.8 ± 0.5 (22) 17.9 ± 0.3 (23)
Brain width (mm) 14.5 ± 0.3 (23) 14.5 ± 0.3 (23) 14.5 ± 0.3 (23) 14.5 ± 0.2 (22) 14.4 ± 0.3 (22) 14.5 ± 0.3 (23)
Morphometric parameters (mm)
Level 1
Ht of hemisphere 0.72 ± 0.02 (10) 0.73 ± 0.02 (10) 0.71 ± 0.02 (10) 0.72 ± 0.03 (10) 0.71 ± 0.03 (9) 0.72 ± 0.02 (10)
Vertical thickness of cortex 0.18 ± 0.01 (10) 0.18 ± 0.01 (10) 0.17 ± 0.01 (10) 0.17 ± 0.01 (10) 0.18 ± 0.01 (9) 0.17 ± 0.01 (10)
178 STUMP ET AL.The DNT study design and statistical analyses for the current
study provided a robust evaluation of potential developmental
neurotoxicity resulting from BPA exposure. The experimental
design included multiple measures for each animal, as well as
testing across time. As the DNT study design might use
multiple littermates for the same test, it was important to
account for the inﬂuence of genetic and maternal factors
contributed by litter as well as the fact that some end points in
these analyses are correlated (e.g., brain weight, length, and
width). Taking these factors into consideration, the statistical
methods employed in this study were based on recent
recommendations from an ILSI Expert Panel for analyses of
neurodevelopmental end points in DNT studies (e.g., including
sex and sex by treatment interactions, litter as the unit of
comparison where appropriate; Holson et al., 2008).
In the present study, the highest two dietary concentrations
met the guideline requirements to induce systemic effects and
achieve a maximum tolerated dose (750 ppm). The two lowest
dietary levels (0.15 and 1.5 ppm) provided daily doses reported
to produce neurobehavioral effects (reviewed by Chapin et al.,
2008); the lowest dose approached higher estimates of adult
human exposure (LaKind and Naiman, 2008). Dietary
concentrations were not adjusted during lactation to offset the
increased feed consumption (i.e., maintaining a more constant
exposure to BPA intake throughout gestation and lactation).
Since dietary concentrations were not adjusted, actual mean
test substance consumption increased approximately threefold
during lactation from 0.03 to 410 mg/kg/day compared with the
target values of 0.01–150 mg/kg/day (Table 1). This was
largely due to the greatly increased measured maternal feed
consumption, and hence increased BPA intake during the last
week of lactation. The increased maternal dose during lactation
likely resulted in a similar increase in the dose relative to the
targeted dose received by the offspring via their lactational
exposure and starting of self-feeding. Hence, not adjusting the
concentration in the diet provided an additional measure of
TABLE 9—Continued
Measurement
BPA dietary concentration (ppm)
0 0.15 1.5 75 750 2250
Level 3
Radial thickness of cortex 0.16 ± 0.01 (10) 0.16 ± 0.01 (10) 0.16 ± 0.01 (10) 0.15 ± 0.01 (10) 0.15 ± 0.01 (10) 0.15 ± 0.01 (10)
Vertical ht between pyramidal
neuron layersþ
0.09 ± 0.01 (10) 0.09 ± 0.00 (10) 0.09 ± 0.00 (10) 0.09 ± 0.01 (10) 0.09 ± 0.01 (10) 0.09 ± 0.01 (10)
Vertical ht of dentate hilus 0.05 ± 0.00 (10) 0.05 ± 0.00 (10) 0.05 ± 0.00 (10) 0.05 ± 0.00 (10) 0.05 ± 0.00 (10) 0.05 ± 0.00 (10)
Length of ventral limb of
dentate hilus
0.14 ± 0.01 (10) 0.14 ± 0.01 (10) 0.13 ± 0.02 (10) 0.13 ± 0.02 (10) 0.13 ± 0.01 (10) 0.14 ± 0.01 (10)
Level 5
Vertical ht of cerebellum 0.48 ± 0.01 (10) 0.47 ± 0.03 (10) 0.46 ± 0.03 (9) 0.47 ± 0.03 (10) 0.46 ± 0.03 (10) 0.47 ± 0.03 (9)
Thickness of the base of
cerebellar lobule 9
0.07 ± 0.00 (10) 0.06 ± 0.00 (10) 0.06 ± 0.01 (9) 0.06 ± 0.00 (10) 0.06 ± 0.00 (10) 0.06 ± 0.01 (10)
PND 72
Terminal body weight (g) 256 ± 17.6 (22) 272 ± 19.4 (23) 256 ± 24.1 (24) 257 ± 21.4 (22) 255 ± 25.4 (22) 253 ± 22.6 (23)
Relative brain weight
(g/100 g body weight)
0.79 ± 0.05 (22) 0.76 ± 0.06 (23) 0.80 ± 0.08 (24) 0.78 ± 0.07 (22) 0.78 ± 0.06 (22) 0.79 ± 0.06 (23)
Brain length (mm) 20.5 ± 0.4 (22) 20.5 ± 0.4 (23) 20.5 ± 0.5 (24) 20.3 ± 0.3 (22) 20.4 ± 0.4 (22) 20.2 ± 0.4 (23)
Brain width (mm) 15.2 ± 0.3 (22) 15.2 ± 0.3 (23) 15.1 ± 0.2 (24) 15.0 ± 0.2 (22) 15.0 ± 0.3 (22) 15.1 ± 0.3 (23)
Morphometric parameters (mm)
Level 1
Ht of hemisphere 0.72 ± 0.02 (10) 0.73 ± 0.03 (10) 0.73 ± 0.02 (10) 0.73 ± 0.03 (10) 0.70 ± 0.03 (10) 0.72 ± 0.04 (10)
Vertical thickness of cortex 0.18 ± 0.00 (10) 0.18 ± 0.01 (10) 0.18 ± 0.01 (10) 0.18 ± 0.01 (10) 0.17 ± 0.01 (10) 0.18 ± 0.01 (10)
Level 3
Radial thickness of cortex 0.17 ± 0.01 (10) 0.17 ± 0.01 (10) 0.17 ± 0.01 (10) 0.17 ± 0.01 (10) 0.17 ± 0.01 (10) 0.16 ± 0.01 (10)
Vertical ht between pyramidal
neuron layersþ
0.09 ± 0.00 (10) 0.10 ± 0.01 (10) 0.09 ± 0.01 (10) 0.09 ± 0.01 (10) 0.09 ± 0.01 (10) 0.09 ± 0.01 (10)
Vertical ht of dentate hilus 0.05 ± 0.00 (9) 0.05 ± 0.00 (9) 0.05 ± 0.00 (9) 0.05 ± 0.00 (10) 0.05 ± 0.00 (9) 0.05 ± 0.00 (10)
Length of ventral limb of
dentate hilus
0.14 ± 0.01 (10) 0.14 ± 0.01 (10) 0.14 ± 0.02 (10) 0.14 ± 0.02 (10) 0.14 ± 0.01 (10) 0.14 ± 0.01 (10)
Level 5
Vertical ht of cerebellum 0.50 ± 0.02 (9) 0.51 ± 0.03 (10) 0.51 ± 0.02 (10) 0.50 ± 0.02 (10) 0.49 ± 0.01 (10) 0.48 ± 0.02 (10)
Thickness of the base of
cerebellar lobule 9
0.07 ± 0.00 (9) 0.07 ± 0.00 (10) 0.07 ± 0.01 (10) 0.07 ± 0.01 (10) 0.08 ± 0.00 (10) 0.07 ± 0.01 (10)
Note. Data are presented as means ± SD of 21–24 animals per group for whole brain measurements and 9–10 animals per group for morphometric parameters at
each age. n in parentheses. When possible, all individual animal data were collected as bilateral measurements. ht, height; þ, measured in the hippocampus.
DEVELOPMENTAL NEUROTOXICITY BPA RAT STUDY 179conservatism in the study design. Exposure of offspring during
gestation and lactation is supported by single-dose pharmaco-
kinetic studies in pregnant rats, which indicate that there was
exposure to the test substance in utero at 10 or 100 mg/kg body
weight (Domoradzki et al., 2003), as well as via the milk while
nursing at 100 mg/kg body weight (Snyder et al., 2000). At the
higher doses used in this DNT study, fetal and neonatal
exposure was likely higher than in the single-dose pharmaco-
kinetic studies due to the repeated dosing and higher maternal
doses.
Treatment-related effects in the present study were limited to
dose-related lower body weight and body weight gain in adults
and reduced feed consumption (all beginning with the initiation
of treatment), as well as lower neonatal body weight. These
effects were evident in the F0 females and F1 males and females
at 750 and 2250 ppm. F1 pup body weight gains were lower
than those of the controls during PNDs 7–14 in the 750- and
2250-ppm dose groups coincident with the increased feed
consumption, and hence increased BPA intake, of the dams
during the second week of lactation. No treatment-related
effects were observed for any parameter at lower doses.
During the DCO of F1 animals, clonic movements were
observed in two pups at 750 ppm and in four pups at 2250 ppm
on PND 11 only. The historical control data indicated that these
ﬁndings have been observed in 2 of 244 females and 0 of
243 males. Since the incidence of these ﬁndings was greater than
the historical control incidence, a follow-up study was conducted
to determine reproducibility and, if appropriate, to further
characterize these ﬁndings. The follow-up study replicated all
aspects of the control and the high-dose groups of the DNT
study through PND 11, but with increased sample size (two pups
per sex per litter and 27 litters for the 2250-ppm dose group). No
effects in the DCO, including the clonic movements observed in
the DNT study on PND 11, were evident (see Supplementary
data); the more deﬁnitive examination in the follow-up study
provides the key evidence that the original observation of clonic
movements was not treatment related. In addition, if the ﬁndings
were treatment related, other observations commonly associated
with treatment-related clonic movements would be expected to
be seen in the DNT study. However, for the six animals showing
clonic movements, there were no remarkable ﬁndings in the
other end points examined as part of the detailed clinical
observations or in the histopathological examination of the
nervous system. Moreover, no treatment-related differences from
controls for motor activity, auditory startle, or learning behavior
were noted in the DNT study (which included the six animals
showing clonic movements). This collective evidence, including
the results from the follow-up study, supports the lack of an
effect by BPA on neurodevelopment.
In conclusion, the extensive evaluations in this DNT study
clearly showed that there were no functional, sensory, or
cognitive deﬁcits resulting from BPA exposure during neuro-
development, nor was there any evidence of effects on the
ontogeny of motor activity. Brain weight, length, and width, as
well as histopathology and morphometry evaluations, also
indicated no treatment-related effects on neurodevelopment. In
addition, there were no developmental delays or evidence of
effects on neurobehavioral development in this study. Since
there were no neurological or neurobehavioral effects at either
high or low doses of BPA, this DNT study provided evidence
that there are no nonmonotonic dose responses for BPA for
these end points. The NOAEL for systemic toxicity based on
body weight reduction was 75 ppm (5.85 and 13.1 mg/kg/day
during gestation and lactation, respectively). The NOAEL for
developmental neurotoxicity of BPA was 2250 ppm (164 and
410 mg/kg/day during gestation and lactation, respectively),
the highest dietary concentration tested. Based on the
conditions of this study, there was no evidence that BPA is
a developmental neurotoxicant in rats.
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